Researchers Submit Patent Application, "Compositions And Methods For Adeno-Associated (Aav) Virus Dnase Expression", for Approval (USPTO 20240425879).

Researchers have submitted a patent application for "Compositions And Methods For Adeno-Associated (AAV) Virus DNase Expression" to the USPTO. The patent focuses on utilizing recombinant adeno-associated virus (rAAV) vectors to deliver deoxyribonuclease (DNase) enzymes for the treatment of diseases involving the accumulation of cell-free DNA. This innovative approach aims to enhance the clearance of cell-free DNA both intravascularly and extravascularly, offering potential therapeutic benefits for various conditions. The patent application outlines the genetic components and mechanisms involved in utilizing rAAV vectors for gene therapy, emphasizing the potential of this technology in addressing genetic diseases and advancing clinical modalities like Crispr/Cas9. [Extracted from the article]